跳至主要内容
临床试验/EUCTR2005-003021-19-GB
EUCTR2005-003021-19-GB进行中(未招募)不适用

The use of selenium and vitamin E supplementation to prevent recurrence and progression of non-muscle-invasive bladder cancer - SELENIB

niversity Of Birmingham0 个研究点开始时间: 2006年9月18日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Able to give informed consent for SELENIB. - An initial diagnosis of: Histopathologically confirmed non-muscle-invasive transitional cell carcinoma (Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Disease characteristics – stage pT2 and above • Patients that are pregnant or breastfeeding • Patients diagnosed with HIV infection • Patients who are on immunosuppressive therapy following organ transplantion • Patients taking cyclosporin • Any condition which, in the opinion of the local investigator, might interfere with the safety of the patient or evaluation of the trial objectives.

研究者

相似试验